Clinical Trials Browser

Terminated × durvalumab × Clear all

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT06083454 2026-03-13

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03753919 2026-03-11

DUTHY

Phase 2 Terminated

79 enrolled 25 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT05443971 2026-02-06

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03075527 2026-01-08

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Phase 2 Terminated

19 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma

NCT04765709 2025-12-16

BRIDGE

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03237377 2025-10-14

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04336943 2025-08-11

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Phase 2 Terminated

6 enrolled 10 charts

Biochemically Recurrent Prostate Carcinoma

NCT04613492 2025-06-24

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT04019288 2025-06-11

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Phase 1 Terminated

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT04441138 2025-05-28

ESR1814205

Phase 2 Terminated

10 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT04108481 2025-03-28

iRE-C

Phase 1 Terminated

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05911308 2025-03-21

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02827838 2025-03-17

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Phase EARLY_PHASE1 Terminated

17 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT06191250 2025-02-03

--SuPERIOR Trial--

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04538378 2025-01-27

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Phase 2 Terminated

4 enrolled 11 charts

EndocrineThoracic

EGFR-Mutated Non-Small-Cell Lung Carcinoma

NCT02891161 2024-11-27

DUART

Phase 1/2 Terminated

26 enrolled 20 charts

Urothelial Cancer

NCT04951115 2024-11-26

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Phase 2 Terminated

6 enrolled 13 charts

Small Cell Lung Carcinoma

NCT04287894 2024-11-06

Induction

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04989218 2024-11-05

ICC

Phase 1/2 Terminated

1 enrolled 11 charts

Gastrointestinal

Cholangiocarcinoma

NCT04866017 2024-10-31

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Phase 3 Terminated

63 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT04348292 2024-08-22

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Phase 1 Terminated

3 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03323398 2024-07-31

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Phase 1/2 Terminated

79 enrolled 18 charts

GynecologicLymphoid

Lymphoma, Ovarian Neoplasms, Recurrence

NCT03199040 2024-05-28

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Phase 1 Terminated

18 enrolled 9 charts

Triple Negative Breast Neoplasms

NCT03810105 2024-04-09

A Study of Olaparib and Durvalumab in Prostate Cancer

Phase 2 Terminated

5 enrolled 4 charts

Prostatic Neoplasms

NCT04610684 2024-03-13

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Phase 2 Terminated

3 enrolled 13 charts

Brain Neoplasms, Small Cell Lung Carcinoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03818776 2024-02-15

Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC

Phase EARLY_PHASE1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03376659 2024-02-05

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Phase 1/2 Terminated

8 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03840902 2024-01-16

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

153 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT03490760 2023-10-12

Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

Phase 2 Terminated

9 enrolled 12 charts

Gastrointestinal

Adenocarcinoma of the Pancreas

NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Phase 2 Terminated

7 enrolled 9 charts

GenitourinarySarcoma

Bladder Adenocarcinoma

NCT03963414 2023-08-28

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Phase 1 Terminated

Small Cell Lung Carcinoma

NCT04372927 2023-06-13

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

Phase 2 Terminated

1 enrolled 10 charts

Lung Neoplasms

NCT03522584 2023-06-12

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Terminated

6 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck

NCT03275597 2023-05-15

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04696848 2023-04-21

The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Phase 1/2 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT02291055 2023-03-20

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Phase 1/2 Terminated

75 enrolled 23 charts

GynecologicHead & Neck

Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms

NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Phase 1 Terminated

6 enrolled 11 charts

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

NCT02901548 2022-07-29

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Phase 2 Terminated

17 enrolled 9 charts

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT03874325 2022-05-31

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase 2 Terminated

17 enrolled 10 charts

Breast Neoplasms

NCT03665129 2022-01-27

STELLAR-001

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumors

NCT03685344 2021-10-26

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Phase 1 Terminated

13 enrolled 15 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04579133 2021-06-16

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Phase 2 Terminated

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03081923 2021-05-14

APACHE

Phase 2 Terminated

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Phase 1/2 Terminated

Solid Cancer

NCT03234153 2020-06-17

NITIMIB

Phase 2 Terminated

Muscle-invasive Bladder Cancer